Table 2.
Univariate and multivariable analyses of clinical characteristics in predicting radiographic response to brain RT
|
Characteristics |
Univariate analysis |
Multivariable analyses |
||||
|---|---|---|---|---|---|---|
| OR | 95% CI of OR | P | OR | 95% CI of OR | P | |
| Age, years (≧60 vs. <60) |
0.48 |
0.13 to 1.81 |
0.277 |
|
|
|
| Gender (male vs. female) |
0.98 |
0.27 to 3.61 |
0.975 |
|
|
|
| Smoking history (ever vs. never) |
0.93 |
0.24 to 3.54 |
0.911 |
|
|
|
| EGFR mutation status (positive vs. negative) |
4.67 |
1.14 to 19.12 |
0.032 |
4.67 |
1.14 to 19.12 |
0.032 |
| Mutant EGFR† (exon 21 vs. exon 19) |
0.42 |
0.06 to 2.77 |
0.369 |
|
|
|
| ECOG performance status |
0.73 |
0.34 to 1.56 |
0.415 |
|
|
|
| RPA class |
|
|
|
|
|
|
| I (reference) |
1 |
-- |
-- |
|
|
|
| II |
0.00 |
0.00 to ∞ |
1.000 |
|
|
|
| III |
0.00 |
0.00 to ∞ |
1.000 |
|
|
|
| Primary tumor status (uncontrolled vs. controlled) |
1.12 |
0.28 to 4.57 |
0.869 |
|
|
|
| Extracranial metastases (present vs. absent) |
2.05 |
0.51 to 8.34 |
0.314 |
|
|
|
| Number of BM (>3 vs. ≦3) |
0.89 |
0.22 to 3.61 |
0.869 |
|
|
|
| Size of largest BM (mm) |
1.07 |
0.99 to 1.15 |
0.091 |
|
|
|
| Hemorrhagic BM (yes vs. no) |
6.00 |
0.68 to 52.90 |
0.107 |
|
|
|
| Total dose (>40 Gy2 vs. ≦40 Gy2) |
1.07 |
0.28 to 4.05 |
0.925 |
|
|
|
| EGFR TKI during RT (yes vs. no) |
0.89 |
0.24 to 3.30 |
0.864 |
|
|
|
| Type of EGFR TKI§ (erlotinib vs. gefitinib) |
1.67 |
0.20 to 14.05 |
0.639 |
|
|
|
| Chemotherapy during RT (yes vs. no) | 2.00 | 0.36 to 11.06 | 0.427 | |||
Abbreviations: OR odds ratio, CI confidence interval, ECOG Eastern Cooperative Oncology Group, RPA recursive partitioning analysis, BM brain metastases, Gy2 biologically equivalent dose equal to fraction size of 2 Gy, TKI tyrosine kinase inhibitor.
† n = 30.
§ n = 19.